RATIONALE: Diabetic cardiovascular complications are reaching epidemic proportions. Angiotensin-converting enzyme-2 (ACE2) is a negative regulator of the renin-angiotensin system. We hypothesize that loss of ACE2 exacerbates cardiovascular complications induced by diabetes. OBJECTIVE: To define the role of ACE2 in diabetic cardiovascular complications. METHODS AND RESULTS: We used the well-validated Akita mice, a model of human diabetes, and generated double-mutant mice using the ACE2 knockout (KO) mice (Akita/ACE2(-/y)). Diabetic state was associated with increased ACE2 in Akita mice, whereas additional loss of ACE2 in these mice leads to increased plasma and tissue angiotensin II levels, resulting in systolic dysfunction on a background of impaired diastolic function. Downregulation of SERCA2 and lipotoxicity were equivalent in Akita and Akita/ACE2KO hearts and are likely mediators of the diastolic dysfunction. However, greater activation of protein kinase C and loss of Akt and endothelial nitric oxide synthase phosphorylation occurred in the Akita/ACE2KO hearts. Systolic dysfunction in Akita/ACE2KO mice was linked to enhanced activation of NADPH oxidase and metalloproteinases, resulting in greater oxidative stress and degradation of the extracellular matrix. Impaired flow-mediated dilation in vivo correlated with increased vascular oxidative stress in Akita/ACE2KO mice. Treatment with the AT1 receptor blocker, irbesartan rescued the systolic dysfunction, normalized altered signaling pathways, flow-mediated dilation, and the increased oxidative stress in the cardiovascular system. CONCLUSIONS: Loss of ACE2 disrupts the balance of the renin-angiotensin system in a diabetic state and leads to an angiotensin II/AT1 receptor-dependent systolic dysfunction and impaired vascular function. Our study demonstrates that ACE2 serves as a protective mechanism against diabetes-induced cardiovascular complications.
RATIONALE: Diabetic cardiovascular complications are reaching epidemic proportions. Angiotensin-converting enzyme-2 (ACE2) is a negative regulator of the renin-angiotensin system. We hypothesize that loss of ACE2 exacerbates cardiovascular complications induced by diabetes. OBJECTIVE: To define the role of ACE2 in diabetic cardiovascular complications. METHODS AND RESULTS: We used the well-validated Akita mice, a model of humandiabetes, and generated double-mutant mice using the ACE2 knockout (KO) mice (Akita/ACE2(-/y)). Diabetic state was associated with increased ACE2 in Akita mice, whereas additional loss of ACE2 in these mice leads to increased plasma and tissue angiotensin II levels, resulting in systolic dysfunction on a background of impaired diastolic function. Downregulation of SERCA2 and lipotoxicity were equivalent in Akita and Akita/ACE2KO hearts and are likely mediators of the diastolic dysfunction. However, greater activation of protein kinase C and loss of Akt and endothelial nitric oxide synthase phosphorylation occurred in the Akita/ACE2KO hearts. Systolic dysfunction in Akita/ACE2KO mice was linked to enhanced activation of NADPH oxidase and metalloproteinases, resulting in greater oxidative stress and degradation of the extracellular matrix. Impaired flow-mediated dilation in vivo correlated with increased vascular oxidative stress in Akita/ACE2KO mice. Treatment with the AT1 receptor blocker, irbesartan rescued the systolic dysfunction, normalized altered signaling pathways, flow-mediated dilation, and the increased oxidative stress in the cardiovascular system. CONCLUSIONS: Loss of ACE2 disrupts the balance of the renin-angiotensin system in a diabetic state and leads to an angiotensin II/AT1 receptor-dependent systolic dysfunction and impaired vascular function. Our study demonstrates that ACE2 serves as a protective mechanism against diabetes-induced cardiovascular complications.
Authors: Christian Heiss; Richard E Sievers; Nicolas Amabile; Tony Y Momma; Qiumei Chen; Shobha Natarajan; Yerem Yeghiazarians; Matthew L Springer Journal: Am J Physiol Heart Circ Physiol Date: 2007-11-30 Impact factor: 4.733
Authors: Eun-Gyoung Hong; Dae Young Jung; Hwi Jin Ko; Zhiyou Zhang; Zhexi Ma; John Y Jun; Jae Hyeong Kim; Andrew D Sumner; Thomas C Vary; Thomas W Gardner; Sarah K Bronson; Jason K Kim Journal: Am J Physiol Endocrinol Metab Date: 2007-10-02 Impact factor: 4.310
Authors: Thomas P Flagg; Olivier Cazorla; Maria S Remedi; Todd E Haim; Michael A Tones; Anthony Bahinski; Randal E Numann; Attila Kovacs; Jean E Schaffer; Colin G Nichols; Jeanne M Nerbonne Journal: Circ Res Date: 2008-11-20 Impact factor: 17.367
Authors: Denise W Wong; Gavin Y Oudit; Heather Reich; Zamaneh Kassiri; Joyce Zhou; Qiao C Liu; Peter H Backx; Josef M Penninger; Andrew M Herzenberg; James W Scholey Journal: Am J Pathol Date: 2007-06-28 Impact factor: 4.307
Authors: Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska Journal: N Engl J Med Date: 2008-11-11 Impact factor: 91.245
Authors: Vaibhav B Patel; Abhijit Takawale; Tharmarajan Ramprasath; Subhash K Das; Ratnadeep Basu; Maria B Grant; David A Hall; Zamaneh Kassiri; Gavin Y Oudit Journal: J Mol Med (Berl) Date: 2015-04-15 Impact factor: 4.599
Authors: Yaqian Duan; Ram Prasad; Dongni Feng; Eleni Beli; Sergio Li Calzi; Ana Leda F Longhini; Regina Lamendella; Jason L Floyd; Mariana Dupont; Sunil K Noothi; Gopalkrishna Sreejit; Baskaran Athmanathan; Justin Wright; Amanda R Jensen; Gavin Y Oudit; Troy A Markel; Prabhakara R Nagareddy; Alexander G Obukhov; Maria B Grant Journal: Circ Res Date: 2019-10-15 Impact factor: 17.367
Authors: Ricardo A Peña Silva; Yi Chu; Jordan D Miller; Ian J Mitchell; Josef M Penninger; Frank M Faraci; Donald D Heistad Journal: Stroke Date: 2012-11-15 Impact factor: 7.914
Authors: Ye Hongwei; Cao Ruiping; Fang Yingyan; Zhang Guanjun; Hu Jie; Liu Xingyu; Tang Jie; Li Zhenghong; Gao Qin; Hu Junfeng; Zhang Heng Journal: Exp Biol Med (Maywood) Date: 2019-04-26